Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Trovagene Launches Urine-Based HPV Test



                   Trovagene Launches Urine-Based HPV Test

New, non-invasive molecular diagnostic test is easy, fast, and accurate

PR Newswire

SAN DIEGO, March 27, 2013

SAN DIEGO, March 27, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV),
today announced the commercial availability of its urine-based HPV-HR
(high-risk) assay, a molecular human papillomavirus (HPV) test. The
non-invasive test is designed to accurately identify the presence or absence
of 15 known high-risk HPV strains using proprietary DNA sequences.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

Approximately 20 million Americans carry HPV, with six million new cases
occurring every year, according to the Centers for Disease Control and
Prevention. By the age of 50, 80 percent of all women will have had exposure
to HPV at some point in their lives. In 2012, the US Preventative Task Force
recommended HPV DNA testing as a mandatory part of the cervical cancer
screening guidelines to help diagnose a greater number of women and thereby
reduce the risk of developing cervical cancer. Currently, less than 40 percent
of women undergo HPV DNA testing in conjunction with a standard Pap smear or
liquid cytology sample.

The Trovagene HPV-HR DNA test is a non-invasive option that may improve the
adoption and acceptance rate of HPV testing. Carrier testing for HPV can help
raise awareness and encourage use of preventative measures to reduce
transmission of the virus. For women who wish to avoid repeated physical
exams, but still need monitoring for their HPV status, a urine-based HPV-HR
DNA test can facilitate more comprehensive patient monitoring.

"The launch of our urine-based HPV-HR DNA test represents an important
milestone for Trovagene," said Antonius Schuh, Ph.D., chief executive officer.
"Non-invasive carrier testing may help to increase awareness of HPV status and
could reduce the incidence of HPV-related cervical cancer and other cancers
worldwide."

The Trovagene HPV-HR test is available to patients through their healthcare
providers. Physicians interested in utilizing the Trovagene assay should
contact Client Services at 888-391-7992. For more information, please visit
www.trovagene.com/HPV. 

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented
technology for the detection of transrenal DNA and RNA, short nucleic acid
fragments, originating from normal and diseased cell death that cross the
kidney barrier and can be detected in urine.  Trovagene is leveraging its
intellectual property in oncogene mutations via out-licensing and use of its
transrenal technologies to extend oncogene mutation detection using urine as a
sample.  As a non-invasive and abundant sample, urine may overcome many of the
cost and collection challenges associated with biopsy, as well as the volume
limitations of blood.

Trovagene has a strong patent position as it relates to transrenal molecular
testing. It has U.S. and European patent applications and issued patents that
cover testing for HPV and other infectious diseases, cancer, transplantation,
prenatal and genetic testing. In addition, it owns worldwide rights to
nucleophosmin-1 (NPM1), an informative biomarker for acute myelogenous
leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be
associated with chemotherapy response in chronic lymphocytic leukemia (CLL)
patients, as well as other hematologic malignancies.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend," among others.
These forward-looking statements are based on Trovagene's current expectations
and actual results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to,
substantial competition; our ability to continue as a going concern; our need
for additional financing; uncertainties of patent protection and litigation;
uncertainties of government or third party payer reimbursement; limited sales
and marketing efforts and dependence upon third parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance with FDA
regulations. As with any medical diagnostic tests under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. There are no guarantees that future
clinical trials discussed in this press release will be completed or
successful or that any product will receive regulatory approval for any
indication or prove to be commercially successful. Trovagene does not
undertake an obligation to update or revise any forward-looking statement. 
Investors should read the risk factors set forth in Trovagene's Form 10-K for
the year ended December 31, 2011 and other periodic reports filed with the
Securities and Exchange Commission.

Contact

Trovagene, Inc.
Keith McCormick
VP, Commercial Operations
+1 (858) 952-7640
kmccormick@trovagene.com
http://www.trovagene.com

SOURCE Trovagene, Inc.

Website: http://www.trovagene.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement